GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · BSE Equity Only

BSE Exchange Filings, Explained Simply

AI-powered plain-English analysis of every important BSE announcement — financial results, order wins, dividends, mergers and more. Updated live.

Today
Total
BSE
Exchange
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings

📋 Filing Types Available on ForgeUp Filings Strictly sourced from BSE exchange announcements (equity segment only). We show only material, important filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India exchange announcements. More categories will be added over time.
Torrent Pharmaceuticals Ltd
Results for quarter ended 30-Jun-26
RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 30 Jul 2026, 04:51 PM IST  ·  BSE ID: 4de8df4b-e882-433b-b3c1-9d96674f62ee
View Original BSE Filing (PDF)
💡
In Simple Terms
Torrent Pharma released its latest quarterly financial results, showing Rs. 492 crores net profit, and completed a merger with JBCPL.
🤖 AI Summary
  • Torrent Pharmaceuticals reported standalone total revenue from operations of Rs. 4158 crores for the quarter ended June 30, 2026.
  • Standalone net profit for the quarter ended June 30, 2026, was Rs. 492 crores.
  • The amalgamation of J.B. Chemicals & Pharmaceuticals Limited (JBCPL) with Torrent Pharma became effective on July 8, 2026.
  • The company allotted 4,19,22,416 equity shares to JBCPL shareholders on July 20, 2026, as part of the amalgamation.
  • Ameera Shah will complete her term as an Independent Director of the company on August 01, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total revenue from operations (Q1 FY27)
Rs. 4158 crores
59.02%
Net profit for the period (Q1 FY27)
Rs. 492 crores
-10.71%
Basic Earnings per Share (Q1 FY27)
Rs. 12.94
-20.40%
Paid-up equity share capital
Rs. 169.23 crores
0.00%
🏢 How This Affects the Company
📈
Business Impact
The amalgamation of JBCPL with Torrent Pharmaceuticals, effective July 8, 2026, consolidates the businesses, impacting future operational scale and market presence.
💰
Financial Impact
The financial results for the quarter ended June 30, 2026, include the standalone financial information of erstwhile JBCPL from January 21, 2026, to March 31, 2026, and reflect the full impact of the merger going forward.
⚙️
Operational Impact
The completion of the amalgamation of JBCPL means the combined entity will integrate operations, likely affecting workforce, manufacturing, and distribution networks.
👥 What This Means For Shareholders
Action Required
Shareholders of Torrent Pharmaceuticals Limited are not required to take any immediate action based on this filing.
👤
Who Is Affected
Existing shareholders of Torrent Pharmaceuticals and former shareholders of JBCPL who received 4,19,22,416 equity shares as part of the amalgamation are affected by the integrated financial performance.
🔍
Management Signal
The completion of the JBCPL amalgamation and the reporting of combined financials signal management's focus on strategic consolidation and expansion through acquisition.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q2 FY27 results — evaluate initial consolidated performance post-amalgamation.
Board meeting updates — monitor any new director appointments or management changes.
Synergy reports — assess integration benefits and cost efficiencies from JBCPL merger.
MEDIUM RISK Integration risks associated with the recent JBCPL amalgamation and a decline in Q1 net profit.
💡 Investor Takeaway
Torrent Pharmaceuticals reported standalone total revenue from operations of Rs. 4158 crores and net profit of Rs. 492 crores for the quarter ended June 30, 2026. The amalgamation of JBCPL became effective on July 8, 2026, impacting financial comparisons.
⚖️ Strengths & Concerns

✅ Positives

  • Total revenue from operations for Q1 FY27 increased to Rs. 4158 crores compared to Rs. 2616 crores in Q1 FY26.
  • Total comprehensive income for Q1 FY27 was Rs. 559 crores, an increase from Rs. 524 crores in Q1 FY26.

⚠️ Concerns

  • Net profit for Q1 FY27 decreased to Rs. 492 crores compared to Rs. 551 crores in Q1 FY26.
  • Basic earnings per share decreased to Rs. 12.94 in Q1 FY27 from Rs. 16.28 in Q1 FY26.
❓ Frequently Asked Questions
What were Torrent Pharmaceuticals' total revenue from operations for the quarter ended June 30, 2026?
Torrent Pharmaceuticals reported total revenue from operations of Rs. 4158 crores for the quarter ended June 30, 2026.
What was Torrent Pharmaceuticals' net profit for the quarter ended June 30, 2026?
The standalone net profit for Torrent Pharmaceuticals for the quarter ended June 30, 2026, was Rs. 492 crores.
When did the amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals become effective?
The Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited became effective on July 8, 2026, with an appointed date of January 21, 2026.
How many equity shares did Torrent Pharmaceuticals allot to JBCPL shareholders?
Torrent Pharmaceuticals Limited allotted 4,19,22,416 fully paid-up equity shares of Rs. 5 each to the eligible shareholders of JBCPL on July 20, 2026.
What is the Basic Earnings per Share for Torrent Pharmaceuticals for Q1 FY27?
The Basic Earnings per Share for Torrent Pharmaceuticals for the quarter ended June 30, 2026, was Rs. 12.94.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.